Position: Home > News

Our hospital has completed the first transrectal high-energy focused ultrasound prostate cancer ablation (AI HIFU) surgery in the northwest

Author:admin      Time:2023-10-09     Number :261
On September 19, 2023, the Urology Department of Xi'an International Medical Center Hospital successfully completed the first transrectal high-energy focused ultrasound prostate cancer ablation (AI HIFU) in the northwest. The application of this technology has opened a new chapter in non-invasive treatment of prostate tumors and benign prostatic hyperplasia in the northwest region.
The patient is a 46-year-old male who accidentally discovered an increase in PSA (Prostate Specific Antigen) during physical examination. After completing the pathology, the patient was diagnosed with prostate cancer and required surgical treatment. The patient is very afraid of traditional invasive surgery and is very concerned about the damage to postoperative urination and sexual function. Based on this, the team led by Yang Zengyue from the Urology Department of Xi'an International Medical Center Hospital implemented a method for the patient to preserve both urinary control and sexual function, Transrectal high-energy focused ultrasound prostate cancer ablation, which can safely and effectively treat prostate cancer.
At 10 o'clock in the morning, the surgery began. The entire process was guided by Director Yang Zengyue and led by Deputy Chief Physician Wang Dong. High intensity focused ultrasound was used through the rectum to focus on the lesion area, using the thermal effect to cause tumor tissue necrosis. The entire surgery process was without bleeding or incision, and the patient returned to the ward safely after the surgery.
According to the results of clinical hospitals in Europe and America, AI HIFU surgery for prostate cancer and benign prostatic hyperplasia can preserve the benign glands, without damage to surrounding tissues, muscles, and functional vascular and neural structures. It has short surgical time, fewer complications, and less bleeding. It is a new generation of "triple win therapy" that can achieve disease control, preserve urinary control, and ensure sexual function.
The successful implementation of this AI HIFU surgery marks the entry of a non-invasive era in the treatment of prostate cancer and benign prostatic hyperplasia in the urology department of our hospital, further alleviating the pain of patients and providing a new treatment option for patients with prostate cancer and benign prostatic hyperplasia.